Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs

Keyphrases

• Aromatic Amino Acid Decarboxylase 100%
• Chronic Treatment 100%
• Tyrosine Hydroxylase 100%
• Dopamine Metabolism 100%
• Haloperidol 40%
• D2-like 40%
• Dopamine 30%
• Chronic Administration 30%
• Dopamine D1 Receptor 20%
• Phenyl 20%
• SCH23390 20%
• Dopamine D1 20%
• Dopamine D2 20%
• 3-Benzazepines 20%
• Change Patterns 10%
• Decarboxylase Activity 10%
• L-DOPA Therapy 10%
• Nigrostriatal Neurons 10%
• Existing Knowledge 10%
• Parkinson Patients 10%
• Enhancement Effect 10%
• Chloro 10%
• Dopamine Agonist 10%
• Quinpirole 10%
• Dopamine D3 10%
• Bromocriptine 10%
• SKF38393 10%
• Dopamine Receptor Antagonist 10%
• D2-D3 10%
• Tetralin 10%
• Drug Challenge 10%
• 7-OH-DPAT 10%
• 8-diol 10%
• 3-methyl-1 10%

Neuroscience

• Metabolic Pathway 100%
• Aromatic L-Amino Acid Decarboxylase 100%
• Dopaminergic 100%
• Tyrosine Hydroxylase 100%
• Haloperidol 40%
• Agonist 30%
• SCH 23390 20%
• D1-Like Receptor 20%
• Benzazepine 20%
• Carboxy-Lyases 10%
• L-DOPA 10%
• Dopamine Agonist 10%
• Quinpirole 10%
• Bromocriptine 10%
• Dopamine Antagonist 10%
• D2-Like Receptor 10%
• Diol 10%
• Tetralin 10%
• Messenger RNA 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Amino Acid Decarboxylase 100%
• Dopamine Receptor Stimulating Agent 100%
• Tyrosine 3 Monooxygenase 100%
• 4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol 40%
• Receptor 30%
• Carboxylyase 10%
• DOPA 10%
• Bromocriptine 10%
• Quinpirole 10%
• Dopamine Receptor Blocking Agent 10%
• Benzazepine Derivative 10%
• 2,3,4,5 Tetrahydro 7,8 Dihydroxy 1 Phenyl 1h 3 Benzazepine 10%
• Messenger RNA 10%